Recruiting

Pulmonary Vein First vs. Pulmonary Artery First

Sponsor:

Thomas Jefferson University

Code:

NCT05502523

Conditions

Lung Non-Small Cell Carcinoma

Stage I Lung Cancer AJCC v8

Stage II Lung Cancer AJCC v8

Stage III Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pulmonary Artery-First Surgical Technique

Biospecimen Collection

Study Details

Brief summary:

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Conditions

Lung Non-Small Cell Carcinoma

Stage I Lung Cancer AJCC v8

Stage II Lung Cancer AJCC v8

Stage III Lung Cancer AJCC v8

Study ID

NCT05502523

Start date

Aug 31, 2022

Status verified date

Jan, 2026

Completion date

Jan 1, 2029

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
  • Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease

Exclusion Criteria:

  • Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
  • Preoperative chemotherapy, immunotherapy, or radiation therapy
  • Receipt of perioperative blood transfusion

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Group I (pulmonary vein first approach procedure)

Patients undergo pulmonary vein first approach surgical procedure on day of surgery.

active comparator: Group II (pulmonary artery first surgical procedure)

Patients undergo pulmonary artery first approach surgical procedure on day of surgery.

Interventions

Pulmonary Artery-First Surgical Technique

Undergo pulmonary artery first surgical technique

Biospecimen Collection

Correlative studies

Primary outcome measure

  • Circulating tumor deoxyribonucleic acid (ctDNA) status [ Time Frame: At postoperative day 2 ]
  • Circulating tumor deoxyribonucleic acid (ctDNA) status [ Time Frame: At postoperative day 14 ]

Central Contacts and Locations

Central contacts

Tyler Grenda, MD

215-955-5562Tyler.grenda@jefferson.edu

Locations

Abington Memorial Hospital

Recruiting

Abington, Pennsylvania, United States, 19001

Contacts

Mary Walicki, RN

215-481-5528mary.walicki@jefferson.edu

Jefferson Health Northeast

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

Joanne Anderson

215-866-8690

Thomas Jefferson University Hospital

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

Tyler Grenda, MD

215-955-5562tyler.grenda@jefferson.edu

Asplundh Cancer Pavilion at Jefferson Health

Recruiting

Willow Grove, Pennsylvania, United States, 19090

Contacts

John Jacob, MD

215-481-4000

More Information

Sponsor

Thomas Jefferson University

Last update posted

Jan 23, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Thomas Jefferson University on 2026-01-23.